Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 3/20 | 0.50 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 6/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3462737 | 1.00 | CENPE (0.50) | CENPEKIFC1S1PR1P2RX3NPC1 | |
| SCHEMBL13642800 | 1.00 | CENPE (0.50) | CENPEKIFC1S1PR1P2RX3NPC1 | |
| SCHEMBL13161508 | 1.00 | CENPE (0.50) | CENPEKIFC1S1PR1P2RX3NPC1 | |
| SCHEMBL10269968 | 0.93 | CENPE (0.49) | CENPEKIFC1S1PR1P2RX3NPC1 | |
| SCHEMBL2103757 | 0.91 | CENPE (0.48) | CENPEKIFC1S1PR1P2RX3NPC1 | |
| SCHEMBL13161868 | 0.91 | CENPE (0.48) | CENPEKIFC1S1PR1P2RX3NPC1 | |
| SCHEMBL3463015 | 0.91 | CENPE (0.49) | CENPEKIFC1S1PR1P2RX3NPC1 | |
| SCHEMBL13626774 | 0.91 | CENPE (0.49) | CENPEKIFC1S1PR1P2RX3NPC1 | |
| SCHEMBL13161791 | 0.91 | CENPE (0.49) | CENPEKIFC1S1PR1P2RX3NPC1 | |
| SCHEMBL3462365 | 0.90 | CENPE (0.52) | CENPEKIFC1S1PR1P2RX3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | CENPE 50/4885KIFC1 5/4885S1PR1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.